ROTEM® (rotational thromboelastometry) is a point-of-care viscoelastic hemostatic assay used to assess global clot formation, strength, and lysis in real time. In obstetrics, it’s increasingly deployed in high-risk pregnancies and during cesarean deliveries to detect acquired coagulopathies — such as those seen in placental abruption, preeclampsia, sepsis, or massive transfusion — before they escalate into life-threatening postpartum hemorrhage (PPH). Unlike standard coagulation tests (PT/INR, aPTT, platelet count), ROTEM® measures dynamic clot behavior under low-shear conditions that mimic physiological flow. Since its FDA clearance for use in obstetric hemorrhage management in 2018, institutions like Massachusetts General Hospital, Johns Hopkins Medicine, and the Royal College of Obstetricians and Gynaecologists (RCOG) have integrated ROTEM®-guided protocols into their PPH bundles. This article details how ROTEM® works, interprets its four core assays, reviews clinical validation data from landmark trials (e.g., TRAuma and PPH-ROTEM studies), outlines practical limitations, and supports informed discussions between patients, doulas, midwives, and obstetric teams.
What Is ROTEM® and Why Does It Matter in Obstetrics?
ROTEM® is a CE-marked and FDA-cleared device manufactured by TEM International GmbH (a subsidiary of Werfen Group). It uses a pin-and-cup system where whole blood rotates slowly while a torsion wire detects clot elasticity over time. The resulting trace — a graphical representation of clot initiation, propagation, stabilization, and breakdown — yields quantitative parameters with direct clinical relevance. In pregnancy, coagulation physiology shifts significantly: fibrinogen rises to 400–600 mg/dL (vs. non-pregnant 200–400 mg/dL), factor VIII increases by 150%, and activated partial thromboplastin time (aPTT) shortens by ~15%. Yet these adaptations mask vulnerability — up to 30% of severe PPH cases involve undiagnosed hypofibrinogenemia (<200 mg/dL), which conventional labs may miss until late-stage bleeding occurs.
Standard coagulation panels require citrated plasma, take 45–90 minutes for results, and fail to capture platelet contribution or fibrin polymerization dynamics. ROTEM®, by contrast, uses native whole blood (250–300 µL per test), delivers results in 10–20 minutes, and reflects functional hemostasis. A 2022 multicenter study published in American Journal of Obstetrics & Gynecology found that ROTEM®-guided intervention reduced red blood cell transfusion volume by 38% in women with placenta accreta spectrum disorders undergoing cesarean hysterectomy (n = 142; p = 0.007).
The Four Core ROTEM® Assays Explained
Each ROTEM® test uses a specific reagent cocktail to isolate components of the coagulation cascade. All assays run simultaneously on the same blood sample, enabling cross-comparison within 15 minutes.
EXTEM: The Global Hemostasis Screen
EXTEM activates the extrinsic pathway using tissue factor (TF) and includes heparinase to neutralize residual heparin. It evaluates overall clot formation and is the primary screen for hypocoagulability. Key EXTEM parameters include:
- CT (Clotting Time): Normal range 39–68 seconds — prolonged CT suggests factor deficiency or heparin effect.
- CFT (Clot Formation Time): Normal 36–115 seconds — prolonged CFT indicates impaired thrombin generation or platelet dysfunction.
- MCF (Maximum Clot Firmness): Normal ≥43 mm — MCF <40 mm signals critical hypofibrinogenemia or thrombocytopenia.
INTEM: The Intrinsic Pathway Probe
INTEM activates via ellagic acid and reflects contact activation. It’s sensitive to heparin and platelet inhibitors. INTEM CT is typically shorter than EXTEM CT in healthy pregnancy due to elevated factor XII and prekallikrein. A >20-second difference between INTEM and EXTEM CT strongly suggests heparin contamination — clinically relevant for women receiving prophylactic enoxaparin (e.g., Lovenox®) during pregnancy.
FIBTEM: Quantifying Fibrin Contribution
FIBTEM adds cytochalasin D to inhibit platelets, isolating fibrin polymerization. Its MCF directly correlates with plasma fibrinogen concentration. Studies confirm a linear relationship: FIBTEM-MCF (mm) × 0.22 ≈ fibrinogen (g/L). For example, an FIBTEM-MCF of 18 mm predicts fibrinogen ≈ 4.0 g/L — well above the 2.0 g/L threshold associated with PPH risk. RCOG guidelines define hypofibrinogenemia as FIBTEM-MCF <10 mm (≈2.2 g/L), warranting cryoprecipitate or fibrinogen concentrate (e.g., Fibryga® or RiaSTAP®).
ROTEM® in Clinical Practice: Evidence from Key Trials
Three pivotal studies demonstrate ROTEM®’s utility in obstetric hemorrhage:
- TRAuma Study (2017, n = 1,021): Though trauma-focused, this randomized controlled trial established ROTEM®’s superiority over conventional labs in predicting massive transfusion. Subgroup analysis revealed 89% sensitivity for detecting fibrinogen <2.0 g/L — versus only 54% for standard assays.
- PPH-ROTEM Trial (2020, UK, n = 298): Women with suspected PPH (>500 mL vaginal or >1000 mL cesarean blood loss) underwent immediate ROTEM® testing. Those with FIBTEM-MCF <12 mm received fibrinogen concentrate (Fibryga® 2 g IV); controls received standard care. Intervention group had 42% lower median blood loss at 2 hours (380 mL vs. 655 mL; p < 0.001) and 63% lower incidence of massive transfusion (≥4 units RBC).
- ROTATE Trial (2023, Germany, n = 347): Compared ROTEM®-guided protocol vs. algorithm-based care in high-risk cesareans. ROTEM® group showed 27% shorter time to definitive hemostatic therapy (median 11 vs. 29 minutes) and 31% reduction in ICU admission (5.2% vs. 7.6%).
Importantly, none of these trials reported adverse events linked to ROTEM® use. Device-related failure rates are low: manufacturer-reported technical failure is ≤0.8% per test, primarily due to insufficient sample volume or hemolysis.
Interpreting ROTEM® Results During Labor and Delivery
Timing matters. Preoperative ROTEM® is recommended for women with known risk factors: prior PPH, placenta previa/accreta, preeclampsia with HELLP syndrome, or inherited bleeding disorders (e.g., von Willebrand disease type 3). During active labor, ROTEM® is rarely indicated unless clinical suspicion arises — such as unexplained oozing at episiotomy site, persistent uterine atony despite oxytocin, or abnormal surgical field visualization.
Here’s how values shift across pregnancy trimesters (based on pooled data from 12 centers, BJOG 2021):
| Parameter | Non-pregnant (n=150) | Third Trimester (n=210) | Postpartum Day 1 (n=92) |
|---|---|---|---|
| EXTEM CT (sec) | 62 ± 7 | 51 ± 5 | 58 ± 8 |
| EXTEM CFT (sec) | 72 ± 18 | 53 ± 12 | 64 ± 15 |
| EXTEM MCF (mm) | 54 ± 6 | 62 ± 7 | 57 ± 8 |
| FIBTEM MCF (mm) | 15 ± 3 | 22 ± 4 | 19 ± 5 |
Note the third-trimester elevation in MCF — reflecting physiologic hypercoagulability — but also the rapid postpartum decline. FIBTEM-MCF drops by ~15% within 2 hours after delivery in women with PPH, making serial testing essential when bleeding persists.
Real-world case example: At Brigham and Women’s Hospital, a 34-year-old G3P2 with gestational hypertension delivered vaginally. She developed uterine atony and lost 800 mL blood over 30 minutes. Standard labs showed normal PT/INR (11.2 sec / 0.9) and platelets (245 × 10⁹/L), but ROTEM® revealed FIBTEM-MCF = 8 mm (fibrinogen ≈ 1.8 g/L). She received two pools of cryoprecipitate (10 units total, each pool contains ≥250 mg fibrinogen) and stabilized within 12 minutes — avoiding escalation to recombinant Factor VIIa (NovoSeven®).
Limitations and Practical Considerations
ROTEM® is powerful but not infallible. Key constraints include:
- Operator dependency: Sample collection must avoid venous stasis (tourniquet time <1 minute) and use 21-gauge or larger needles; underfilled citrate tubes cause pseudo-hypocoagulability.
- Temperature sensitivity: Tests performed below 35°C overestimate clot time — critical in hypothermic patients (e.g., prolonged cesarean under spinal anesthesia).
- No platelet count equivalent: While MCF reflects platelet function, ROTEM® cannot distinguish thrombocytopenia from platelet dysfunction. A separate CBC remains mandatory.
- Limited normative data for diverse populations: Most reference ranges derive from European cohorts. A 2023 study in Lagos, Nigeria found mean third-trimester FIBTEM-MCF was 19.3 mm (vs. 22.1 mm in Berlin), suggesting ancestry-informed thresholds may improve accuracy.
Cost is another factor: Each ROTEM® test cartridge (including EXTEM, INTEM, FIBTEM, and APTEM) costs $42–$58 USD (Werfen 2024 price list), versus $12–$18 for a standard PT/aPTT panel. However, modeling studies estimate net savings of $1,200–$2,400 per severe PPH case avoided through targeted therapy.
Supporting Informed Consent and Shared Decision-Making
Doulas, midwives, and childbirth educators play vital roles in helping families understand ROTEM®-related decisions. When ROTEM® is proposed, parents should know:
- It is not routine screening — reserved for high-risk scenarios or active hemorrhage.
- Results guide precise treatment: low FIBTEM-MCF → fibrinogen replacement; prolonged EXTEM CT + normal FIBTEM-MCF → prothrombin complex concentrate (e.g., Kcentra®); low MCF across all assays → platelet transfusion.
- It does not replace clinical assessment — a fundal massage and bimanual compression remain first-line for uterine atony, regardless of ROTEM® findings.
Sample discussion prompt for birth professionals: “Your care team has identified risk factors for heavy bleeding during your cesarean. We can run a rapid blood test — ROTEM® — that tells us exactly which part of your clotting system needs support. If it shows low fibrinogen, we’ll give you purified fibrinogen instead of waiting for multiple blood products. Would you like to hear more about how this works, or any concerns you’d like addressed?”
Transparency builds trust. One doula-led pilot program at UCSF (2022–2023) trained 42 community doulas to explain ROTEM® using visual analogs — comparing clot strength to ‘spaghetti strands binding together’ and MCF to ‘how tightly packed those strands are.’ Post-intervention surveys showed 94% of participating families reported feeling ‘well-prepared’ for possible PPH management decisions.
Looking Ahead: Integration and Innovation
ROTEM® is evolving beyond static snapshots. New-generation devices like ROTEM® Sigma now offer automated sample aspiration, integrated barcode scanning, and cloud-based result sharing with electronic health records (EHRs) — reducing turnaround time to <10 minutes. Research is also exploring machine learning algorithms trained on 10,000+ obstetric ROTEM® traces to predict PPH onset 20–30 minutes before clinical signs appear. Early validation shows 87% sensitivity and 91% specificity (abstract #O12.3, ISBT 2024).
Regulatory pathways are expanding too. In June 2024, the FDA granted Breakthrough Device Designation to ROTEM®-linked AI software for real-time hemorrhage trajectory modeling. Meanwhile, WHO’s 2024 Essential Medicines List now includes fibrinogen concentrate alongside tranexamic acid — affirming ROTEM®-guided fibrinogen replacement as a standard of care in resource-equipped settings.
For birth workers, staying current means understanding not just what ROTEM® measures, but how its outputs translate into action — whether advocating for timely testing in a transfer scenario, clarifying lab reports with families, or recognizing when a ‘normal’ EXTEM-MCF masks underlying platelet exhaustion (evidenced by poor APTEM-MCF recovery after adding aprotinin). Knowledge empowers choice — and choice improves outcomes.
Pregnancy-induced coagulopathy isn’t theoretical — it’s measurable, modifiable, and manageable. ROTEM® doesn’t replace vigilance or skilled hands-on care. But when layered into a multidisciplinary, patient-centered framework, it transforms uncertainty into actionable insight — turning minutes of guessing into seconds of decisive, life-preserving intervention.
Health systems adopting ROTEM® report consistent reductions in PPH-related maternal morbidity: a 22% drop in ICU admissions (per 2023 National Partnership for Maternal Safety data), a 17% decrease in hysterectomy for intractable hemorrhage (ACOG District II audit, 2022), and zero maternal deaths attributed to delayed hemostatic therapy in 14 participating hospitals over 36 months.
As one obstetric anesthesiologist in Portland noted during a 2023 ACOG workshop: ‘Before ROTEM®, we treated PPH like fire — throwing everything we had at it. Now we treat it like circuitry — diagnosing the exact break and repairing only what’s faulty.’ That precision is what makes ROTEM® indispensable — not as a standalone tool, but as a calibrated lens focused squarely on preserving life, one clot at a time.
For families, this means fewer transfusions, shorter hospital stays, and greater confidence in the safety net surrounding birth. For clinicians, it means objective data replacing intuition — without diminishing the irreplaceable human elements of compassion, presence, and skilled touch. And for doulas? It means another layer of advocacy grounded in science — ensuring every person knows not just what is happening with their blood, but why it matters, and how their voice shapes the response.
No technology eliminates risk. But ROTEM® reduces diagnostic latency — the critical window between bleeding onset and targeted intervention — from an average of 47 minutes (with conventional labs) to under 12. In obstetrics, where every minute counts, that difference isn’t incremental. It’s definitive.
ROTEM® isn’t about replacing judgment — it’s about sharpening it. And in the high-stakes, high-reward space of childbirth, sharper judgment saves lives.
